LENZ Therapeutics, Inc. SEC filings LENZ
LENZ Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations, exit or restructuring costs, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Jul 30, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LENZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815776
- Former names
- Graphite Bio, Inc. (until Mar 19, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.